Literature DB >> 3163860

Study of HLA antigens in a population of Mali (West Africa).

I Kalidi1, Y Fofana, A A Rahly, V Bochu, C Dehay, J Gony, J Hors.   

Abstract

Eighty-two healthy individuals have been typed for HLA-A, B, C, antigens, and 49 of them also for HLA DR alleles. They were a sample representative of 11 of the 14 Malian ethnic groups living in the area of Bamako (Mali). Phenotypic frequencies have been compared to those of other Negroid and Caucasoid reference populations. As expected, in Negroids the increased frequency of HLA A23, A28, A30, and ATh was confirmed in the present series. Additionally, a significantly increased frequency of HLA B5 (B51 and Bw52) was noted--already observed in some but not all Negroid populations. Conversely, a decreased frequency--compared with that usually found in Negroid population--was observed for the alleles Bw42, Bw58, Cw6, and DRw6. Our results underline the originality of the Malian population among Western Africans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3163860     DOI: 10.1111/j.1399-0039.1988.tb02070.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  10 in total

1.  HLA-DR polymorphism in a Senegalese Mandenka population: DNA oligotyping and population genetics of DRB1 specificities.

Authors:  J M Tiercy; A Sanchez-Mazas; L Excoffier; X Shi-Isaac; M Jeannet; B Mach; A Langaney
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

2.  Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia.

Authors:  C E Allsopp; R M Harding; C Taylor; M Bunce; D Kwiatkowski; N Anstey; D Brewster; A J McMichael; B M Greenwood; A V Hill
Journal:  Am J Hum Genet       Date:  1992-02       Impact factor: 11.025

3.  Human leukocyte antigen class I haplotypes of human immunodeficiency virus-1-infected persons on Likoma Island, Malawi.

Authors:  Otto O Yang; Martha J Lewis; Elaine F Reed; David W Gjertson; Linda Kalilani-Phiri; James Mkandawire; Stéphane Helleringer; Hans-Peter Kohler
Journal:  Hum Immunol       Date:  2011-05-24       Impact factor: 2.850

4.  Analysis of HLA-DR and -DQ gene polymorphisms in Sudanese patients with type 1 (insulin-dependent) diabetes.

Authors:  M M Magzoub; H A Stephens; E A Gale; G F Bottazzo
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

5.  Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria.

Authors:  Joseph C Forbi; Gilberto Vaughan; Michael A Purdy; David S Campo; Guo-liang Xia; Lilia M Ganova-Raeva; Sumathi Ramachandran; Hong Thai; Yury E Khudyakov
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

Review 6.  Spondyloarthritis in sub-Saharan Africa.

Authors:  Mohammed Tikly; Panganani Njobvu; Paul McGill
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

7.  Ankylosing spondylitis in rheumatology patients in Ouagadougou (Burkina Faso).

Authors:  Dieu-Donné Ouédraogo; Hervé Tiéno; Hyacinthe Kaboré; Elisabeth Palazzo; Oliver Meyer; Joseph Youssouf Drabo
Journal:  Clin Rheumatol       Date:  2009-09-02       Impact factor: 2.980

Review 8.  Rheumatic diseases in Africa.

Authors:  Olufemi Adelowo; Girish M Mody; Mohammed Tikly; Omondi Oyoo; Samy Slimani
Journal:  Nat Rev Rheumatol       Date:  2021-04-13       Impact factor: 20.543

9.  The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa.

Authors:  Daniel R Jacobson; Alice A Alexander; Clement Tagoe; W T Garvey; Scott M Williams; Sara Tishkoff; David Modiano; Sodiomon B Sirima; Issa Kalidi; Amadou Toure; Joel N Buxbaum
Journal:  Mol Genet Genomic Med       Date:  2016-07-14       Impact factor: 2.183

10.  An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.

Authors:  C V Herst; S Burkholz; J Sidney; A Sette; P E Harris; S Massey; T Brasel; E Cunha-Neto; D S Rosa; W C H Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen
Journal:  Vaccine       Date:  2020-04-28       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.